| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 3, 2026
Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of...
-
Apr 20, 2026
CathWorks FFRangio® System employs drug-free, wire-free technology for comprehensive physiological assessment GALWAY, Ireland, April 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global...
-
Mar 23, 2026
Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc (NYSE:...
-
Feb 3, 2026
Deal demonstrates Medtronic's commitment to expanding pipeline through strategic investments and targeted acquisitions Exercising option to acquire will bolster Medtronic's interventional...
-
Apr 25, 2025
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025:...
-
Jan 13, 2025
European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY, Ireland, Jan. 13, 2025...
-
May 17, 2024
Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneously published in Heart Rhythm DUBLIN and BOSTON, May 17, 2024...
-
Apr 8, 2024
EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation System DUBLIN and BERLIN, April...
-
Aug 28, 2022Medtronic Extravascular ICD meets global pivotal clinical trial's safety and effectiveness endpoints
Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success DUBLIN and BARCELONA,
-
Jan 21, 2022- Multi-year partnerships to serve over 60,000 underserved and underrepresented K-12 students in Minnesota, Northern California and Puerto Rico
The Medtronic Foundation today announced 13 new partnerships with leading organizations serving underrepresented and underserved K-12 students in Minnesota, Northern California and Puerto Rico....
-
Nov 15, 2021Latest approval for PillCam™ further enables patients to receive gastrointestinal care in the comfort of their own home
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its PillCam™ Small Bowel 3...
-
Sep 30, 2021Industry Leading Portfolio of Integrated Solutions Sets a New Standard for Minimally Invasive Spine Procedures, Beginning with MIS+ TLIF
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine...
-
Sep 28, 2021- Portfolio Features First Catheter Specifically Designed to Allow Neurointerventionalists Radial Artery Access, Delivers Advantages to Patients Treated for Stroke, Brain Aneurysms, Other Neurovascular Conditions
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE Mark approval for its radial artery access portfolio, which includes the Rist™ 079 Radial...
-
Sep 7, 2021
Results Demonstrate Feasibility of Bronchoscopic Microwave Ablation for Certain Patients with Malignant Lung Nodules DUBLIN, Sept. 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global...
-
Aug 24, 2021Evolut™ FX TAVR System Adds Innovative Features to Enhance Ease-of-Use and Predictable Valve Deployment
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic...
-
Jun 7, 2021The SenSight™ Directional Lead System Was Designed to Enable Precision, Personalization and Enhanced Patient Comfort
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) approval and first U.S. implants of the SenSight™ Directional Lead...
-
May 10, 2021SonarMed™ Airway Monitoring System Continuously Checks for Endotracheal Tube Obstruction and Position for Neonates and Infants Providing Immediate, Actionable Intelligence for Clinicians
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. commercial launch of the SonarMed™ airway monitoring system. The first and only device of its kind,...
-
Apr 26, 2021SyncAR™ Technology Uniquely Integrates with StealthStation™ S8 Surgical Navigation System and Expands the Use of Augmented Reality Into Operating Rooms to Enhance Precision and Efficiency
Medtronic plc (NYSE:MDT), the global leader in medical technology, and Surgical Theater today announced a partnership to interface Surgical Theater's SyncAR™ augmented reality (AR) technology...
-
Apr 7, 2021New Partnerships and Research Efforts Prioritized Over the Next Three Years to Address Health Disparities
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its ongoing commitment to health equity for people of color living with diabetes. The company committed...
-
Mar 22, 2021
This First-of-its-Kind Directional Lead Combines the Benefits of Directionality with the Power of Sensing DUBLIN, March 22, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in...
-
Mar 17, 2021Revised Commercial Labeling to Reflect Outcomes of a Randomized Controlled Trial Demonstrating Superiority of DTM™ Spinal Cord Stimulation (SCS) Compared to Conventional SCS for the Treatment of Chronic Intractable Back Pain
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis™...
-
Feb 18, 2021
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for expanded MRI labeling of...
-
Jan 29, 2021Clinical Trial Demonstrates Procedural Efficiencies, Safety, Effectiveness and Non-Inferiority of DiamondTemp System
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of the DiamondTemp™ Ablation (DTA) system...
-
Jan 14, 2021
ADAPT-PD Global Study Designed to Demonstrate Safety & Efficacy of Automated Therapy Which Responds to Brain Signals in Parkinson's Disease Patients DUBLIN, Jan. 14, 2021 /PRNewswire/ -- Medtronic...
-
Dec 15, 2020The OPuS One Clinical Study is the largest study with the most meaningful clinical results supporting the OsteoCool™ Technology to-date
Medtronic plc (NYSE: MDT) today announced the release of outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation (RFA) System in the OPuS One Clinical Study (as...
